These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 617255)

  • 21. Lymphocyte alteration by procainamide: relation to drug-induced lupus erythematosus syndrome.
    Bluestein HG; Zvaifler NJ; Weisman MH; Shapiro RF
    Lancet; 1979 Oct; 2(8147):816-9. PubMed ID: 90917
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Inflammatory demyelinating diseases if the peripheral nervous system: immunological concepts and experimental models].
    Vass K; Lassmann H
    Wien Klin Wochenschr Suppl; 1991; 190():13-6. PubMed ID: 1771901
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The Guillain-Barré syndrome].
    Piradov MA; Lozhnikova SM; Sakharova AV; Liudkovskaia IG; Nikitin SS
    Arkh Patol; 1994; 56(5):73-9. PubMed ID: 7535047
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Procainamide-induced SLE and lymphoreticular disorders.
    Artinian B; Reesal M
    Can Med Assoc J; 1974 Feb; 110(3):314 passim. PubMed ID: 4812149
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neuropathy of gastrointestinal Chagas' disease: immune response to myelin antigens.
    Oliveira EC; Fujisawa MM; Hallal Longo DE; Farias AS; Contin Moraes J; Guariento ME; de Almeida EA; Saad MJ; Langone F; Toyama MH; Andreollo NA; Santos LM
    Neuroimmunomodulation; 2009 Jan; 16(1):54-62. PubMed ID: 19077446
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mitochondrial schwannopathy and peripheral myelinopathy in a rabbit model of dideoxycytidine neurotoxicity.
    Anderson TD; Davidovich A; Feldman D; Sprinkle TJ; Arezzo J; Brosnan C; Calderon RO; Fossom LH; DeVries JT; DeVries GH
    Lab Invest; 1994 May; 70(5):724-39. PubMed ID: 7515130
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pure red cell aplasia in procainamide induced systemic lupus erythematosus. Report and review of the literature.
    Agudelo CA; Wise CM; Lyles MF
    J Rheumatol; 1988 Sep; 15(9):1431-2. PubMed ID: 3143834
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Supernumerary schwann cells during remyelination of regenerated and segmentally demyelinated axons in peripheral nerves].
    Schröder JM
    Verh Dtsch Ges Pathol; 1968; 52():222-8. PubMed ID: 4182232
    [No Abstract]   [Full Text] [Related]  

  • 29. Inhibition of Con A mitogenesis by serum from procainamide-treated patients and patients with systemic lupus erythematosus.
    Tannen RH; Cunningham-Rundles S
    Immunol Commun; 1982; 11(1):33-45. PubMed ID: 6178682
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Crithidia luciliae assay for antibodies to native DNA in procainamide-induced lupus erythematosus.
    Dixon JA; Mulhern LM; Whiteside TL; Luksick J
    J Rheumatol; 1980; 7(4):544-6. PubMed ID: 6999152
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Studies on a circulating anticoagulant in procainamide-induced lupus erythematosus.
    Edwards RL; Rick ME; Wakem CJ
    Arch Intern Med; 1981 Nov; 141(12):1688-90. PubMed ID: 6171218
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Chronic inflammatory demyelinating polyradiculoneuropathy presenting localized radiculopathy as an initial symptom].
    Kuwabara S; Kawamura M; Nagumo K; Kitano K; Hirayama K
    Rinsho Shinkeigaku; 1991 Mar; 31(3):310-3. PubMed ID: 1893672
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neuropathological comparative studies on experimental allergic neuritis (EAN) induced in rabbits by P2 protein-ganglioside complexes.
    Takeda S; Ikuta F; Nagai Y
    Jpn J Exp Med; 1980 Dec; 50(6):453-62. PubMed ID: 6168787
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunomodulatory effects of procainamide metabolites: their implications in drug-related lupus.
    Adams LE; Sanders CE; Budinsky RA; Donovan-Brand R; Roberts SM; Hess EV
    J Lab Clin Med; 1989 Apr; 113(4):482-92. PubMed ID: 2539420
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Kinetics of anti-peripheral nerve myelin antibody in patients with Guillain-Barré syndrome treated and not treated with plasmapheresis.
    Vriesendorp FJ; Mayer RF; Koski CL
    Arch Neurol; 1991 Aug; 48(8):858-61. PubMed ID: 1898263
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug-induced dysimmune demyelinating neuropathies.
    Stübgen JP
    J Neurol Sci; 2011 Aug; 307(1-2):1-8. PubMed ID: 21621795
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Guillain-Barré syndrome as a manifestation of systemic lupus erythematosus. Report of a case].
    Moreira Filho PF; Nascimento OJ; Cinnicinatus D; Porto FJ; Freitas MR; Santos PC
    Arq Neuropsiquiatr; 1980 Jun; 38(2):165-70. PubMed ID: 7436800
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinicopathological study of a patient with procainamide-induced systemic lupus erythematosus.
    Levo Y; Pick AI; Avidor I; Ben-Bassat M
    Ann Rheum Dis; 1976 Apr; 35(2):181-5. PubMed ID: 942276
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acute and chronic demyelinating inflammatory polyradiculoneuropathy. Association with autoimmune diseases and lymphocyte response to human neuritogenic protein.
    Korn-Lubetzki I; Abramsky O
    Arch Neurol; 1986 Jun; 43(6):604-8. PubMed ID: 2424413
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antibody binding to PNS myelin proteins in acute Guillain-Barré syndrome.
    Shuman S; Zweiman B; Lisak R; Kahn S; Rostami A; Sumner A
    Pathol Immunopathol Res; 1988; 7(3):162-8. PubMed ID: 3194353
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.